Home - Synopulse

Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four

Admin July 21, 2026

CI Neurology/Medtech/Neuromodulation Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four Athithi Verma· 21 July 2026· 1 min read· Synopulse Biotronik Neuro launched…

Tempus to acquire Personalis for $1.5B, buying the MRD test it already commercialised

Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold

OrphanPulse Wk 29: Ionis Takes SMA-Proven Antisense Into Dravet Syndrome

NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

Editor’s Pick

Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four

Admin July 21, 2026

Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold

Admin July 21, 2026

The Pulse

No post found!

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

Athithi July 19, 2026

The Signal

No post found!

NeuroPulse

No post found!

Deal Room

No post found!

Access Watch

No post found!

NICE Backs Finerenone for 280,000 Heart Failure Patients

July 17, 2026

NICE Slashes Medicines Evaluation Times by 30%

July 17, 2026

Germany has passed healthcare reforms despite pharma's resistance, hiking the fixed rebate on branded drugs from 7% to 15.5% to save €16.3 billion next year.

Germany Defies Pharma Backlash, Hikes Drug Rebate to 15.5%

July 15, 2026

What’s Next

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

July 19, 2026

NICE Backs Finerenone for 280,000 Heart Failure Patients

July 17, 2026

NICE Slashes Medicines Evaluation Times by 30%

July 17, 2026

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

July 16, 2026